Quarterly report pursuant to Section 13 or 15(d)

Revenue (Details)

v3.4.0.3
Revenue (Details)
$ in Thousands, £ in Millions
 1 Months Ended 3 Months Ended 6 Months Ended 19 Months Ended
Jun. 30, 2014
GBP (£)
Jun. 30, 2014
USD ($)
Mar. 31, 2016
USD ($)
Milestone
item
Mar. 31, 2015
USD ($)
Dec. 31, 2015
USD ($)
Dec. 31, 2015
GBP (£)
Dec. 31, 2015
USD ($)
Revenue from collaborations and license agreements              
Revenue recognized     $ 2,918 $ 2,728 $ 8,979    
Collaborative arrangement | GlaxoSmithKline Intellectual Property Development Ltd              
Revenue from collaborations and license agreements              
Number of additional target peptides, that the entity has right to nominate | item     4        
Upfront payment received £ 25 $ 42,000          
Milestone payments received           £ 14 $ 22,000
Number of milestones achieved during the period | Milestone     0        
Royalties received     $ 0        
Written notice period required to be served for the termination of agreement for material breach (in days)     60 days        
Notice period required to be served for the termination of agreement or specific program (in days)     60 days        
Maximum combination studies permitted | item     8        
Revenue recognized     $ 2,918 $ 2,728